Maze Therapeutics (MAZE) SVP logs option, RSU grants and sale
Rhea-AI Filing Summary
Maze Therapeutics SVP, Finance Amy Bachrodt reported multiple equity transactions on March 2, 2026. She exercised a stock option for 5,000 shares of common stock at $10.42 per share and received a new stock option grant for 32,000 shares plus 16,000 restricted stock units, all held directly.
On the same date, she sold 1,300 shares of common stock at a weighted average price of $44.4414 and 3,700 shares at a weighted average price of $45.4694, in open‑market transactions under a Rule 10b5‑1 trading plan adopted on September 29, 2025. The footnotes note price ranges for these weighted averages and describe monthly vesting for the options and annual vesting tranches for the RSUs, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 5,000 shares ($174K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Bachrodt Amy
Role
SVP, Finance
Sold
5,000 shs ($226K)
Approx. gross sale proceeds
$226K
Approx. exercise cost
$52K
Approx. pre-tax spread
$174K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 32,000 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units | 16,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,000 | $10.42 | $52K |
| Sale | Common Stock | 1,300 | $44.4414 | $58K |
| Sale | Common Stock | 3,700 | $45.4694 | $168K |
Holdings After Transaction:
Stock Option (Right to Buy) — 68,333 shares (Direct);
Restricted Stock Units — 16,000 shares (Direct);
Common Stock — 12,965 shares (Direct)
Footnotes (8)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.99 per share, inclusive.
- F4. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
- F5. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.
- F6. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- F7. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.
- F8. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Maze Therapeutics (MAZE) SVP Amy Bachrodt report on this Form 4?
Amy Bachrodt reported a mix of equity transactions, including option exercises, new option and RSU grants, and open-market share sales. All transactions occurred on March 2, 2026, and relate to Maze Therapeutics common stock and derivative equity awards held directly.
What equity awards did Amy Bachrodt receive from Maze Therapeutics on March 2, 2026?
She received a stock option grant for 32,000 shares and a restricted stock unit grant for 16,000 units. The option vests monthly over 48 months starting April 1, 2026, while the RSUs vest in four equal annual tranches beginning March 1, 2027, subject to continued service.
How do Amy Bachrodt’s Maze Therapeutics options and RSUs vest over time?
One option referenced vests in monthly installments of 1/48 of the total award starting January 1, 2025. The new option vests monthly over 48 months from April 1, 2026. The RSUs vest 25% annually, beginning March 1, 2027, conditioned on continued service.
What does each restricted stock unit represent in this Maze Therapeutics Form 4?
Each restricted stock unit represents a contingent right to receive one share of Maze Therapeutics common stock upon settlement. The footnotes clarify these RSUs do not expire but will either vest on scheduled dates or be cancelled if vesting conditions, including continued service, are not met.